Literature DB >> 7505056

Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study.

D K Giri1, S N Wadhwa, S N Upadhaya, G P Talwar.   

Abstract

The expression of the neu oncogene product was investigated immunohistochemically in 36 cases of benign prostatic hyperplasia (BPH) and seven cases of adenocarcinoma of prostate (CaP). c-neu oncogene encodes a transmembrane growth factor receptor that has partial structural homology with EGF receptor, and is overexpressed and amplified in a number of human tumors, specially, breast cancers. Using a monoclonal antibody, AB-3, which recognizes -COOH-terminal of neu oncoprotein, we have analyzed immunohistochemically the expression of this protein in buffered formalin and Zamboni fluid-fixed surgically removed tissues. Focal patchy and/or diffused cytoplasmic staining of varying intensity was observed in 34 of 36 BPH cases. Four cases showed cell membrane staining as well (4/36 = 11%). All seven cases of adenocarcinomas had moderate to strong c-neu immunoreactivity, and two gave a distinct cell membrane-positive reaction (100%). The available data indicate that prostatic tumors as well as a high percentage of prostatic hyperplasia tissues express c-neu protein; however, its role in cellular proliferation needs further study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505056     DOI: 10.1002/pros.2990230406

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

1.  Analysis of protooncogene c-erbB-2 in benign and malignant human prostate.

Authors:  M Watanabe; T Nakada; H Yuta
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

2.  ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells.

Authors:  Jessica Tome-Garcia; Dan Li; Seda Ghazaryan; Limin Shu; Lizhao Wu
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.